Literature DB >> 1614382

Federal budgetary costs of blindness.

Y P Chiang1, L J Bassi, J C Javitt.   

Abstract

Federal expenditures for blindness-related disability among Americans are examined. The government, rather than the private sector, frequently bears the economic consequences of visual disability through entitlement and public assistance programs. Findings suggest an average $11,896 federal cost of a person-year of blindness for a working-aged American, which includes income assistance programs (SSDI/SSI), health insurance programs (Medicare/Medicaid), and tax losses resulting from reduced potential earnings. Almost 97 percent of the aggregate annual federal costs of blindness in 1990, which totaled approximately $4 billion, is accounted for by working-aged adults, who represent less than one-third of the total blind population. Approximately 25 percent of all blindness is attributed to preventable causes.

Entities:  

Mesh:

Year:  1992        PMID: 1614382

Source DB:  PubMed          Journal:  Milbank Q        ISSN: 0887-378X            Impact factor:   4.911


  14 in total

Review 1.  What is the cost of blindness?

Authors:  C Meads; C Hyde
Journal:  Br J Ophthalmol       Date:  2003-10       Impact factor: 4.638

2.  Childhood blindness and visual loss: an assessment at two institutions including a "new" cause.

Authors:  M B Mets
Journal:  Trans Am Ophthalmol Soc       Date:  1999

Review 3.  The possible impact of uveitis in blindness: a literature survey.

Authors:  M S Suttorp-Schulten; A Rothova
Journal:  Br J Ophthalmol       Date:  1996-09       Impact factor: 4.638

Review 4.  Corneal blindness and xenotransplantation.

Authors:  Vladimir Lamm; Hidetaka Hara; Alex Mammen; Deepinder Dhaliwal; David K C Cooper
Journal:  Xenotransplantation       Date:  2014-02-21       Impact factor: 3.907

5.  Cost savings associated with detection and treatment of diabetic eye disease.

Authors:  J C Javitt
Journal:  Pharmacoeconomics       Date:  1995       Impact factor: 4.981

6.  Cost utility of photodynamic therapy for predominantly classic neovascular age related macular degeneration.

Authors:  C Hopley; G Salkeld; P Mitchell
Journal:  Br J Ophthalmol       Date:  2004-08       Impact factor: 4.638

7.  Evaluation of non-medical costs associated with visual impairment in four European countries: France, Italy, Germany and the UK.

Authors:  Antoine Lafuma; Antoine Brézin; Stefania Lopatriello; Klaus Hieke; Julia Hutchinson; Viviane Mimaud; Gilles Berdeaux
Journal:  Pharmacoeconomics       Date:  2006       Impact factor: 4.981

8.  Ocular injuries from fireworks: the 11-year experience of a US level I trauma center.

Authors:  I T Chang; M A Prendes; K J Tarbet; A J Amadi; S-H Chang; S S Shaftel
Journal:  Eye (Lond)       Date:  2016-06-10       Impact factor: 3.775

9.  Cost utility of screening and treatment for early age related macular degeneration with zinc and antioxidants.

Authors:  C Hopley; G Salkeld; J J Wang; P Mitchell
Journal:  Br J Ophthalmol       Date:  2004-04       Impact factor: 4.638

10.  Activity of daily living and its associated factors in war survivors with no visual acuity.

Authors:  Reza Amini; Hamid Haghani; Mehdi Masoomi; Shervin Assari
Journal:  J Res Med Sci       Date:  2010-07       Impact factor: 1.852

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.